Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNMD Stock Price Chart Interactive Chart >
MNMD Price/Volume Stats
|Current price||$2.70||52-week high||$32.25|
|Prev. close||$2.70||52-week low||$2.35|
|Day high||$2.74||Avg. volume||590,216|
|50-day MA||$3.31||Dividend yield||N/A|
|200-day MA||$10.43||Market Cap||101.44M|
Mind Medicine (MindMed) Inc. (MNMD) Company Bio
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Most Popular Stories View All
MNMD Latest News Stream
|Loading, please wait...|
MNMD Latest Social Stream
View Full MNMD Social Stream
Latest MNMD News From Around the Web
Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
While you’re looking for the perfect holiday bargains to put under the tree, this is also an ideal time to clear your portfolio from F-rated stocks to sell.
SHERIDAN, Wyo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) announces that it has sent a letter (the “Letter”) to the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (“MindMed”, the “Company”). On November 10, 2022, MindMed filed with the Securities and Exchange Commission (the “SEC”) form 10-Q for quarter three of 2022 (the “ER”). The Letter focuses on false statements made by MindMed in the ER whereby MindMed, among other errors, underre
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2022.
Trouble abounds as Mind Medicine proposes a huge sale of MNMD stock shares and an activist investor threatens the company's board.
MNMD Price Returns